Download PDF
Diabetes aktuell 2008; 6(3): 105-112
DOI: 10.1055/s-0028-1082172
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Wo stehen wir? – Blutzuckersenkung zur Reduktion des kardiovaskulären Risikos

Where are we today ? – Reduction of blood glucose for the reduction of cardiovascular riskDirk Müller–Wieland1
  • 1I. Medizinische Abteilung und Institut für Diabetes–Forschung, Asklepios Klinik St. Georg, Hamburg
Further Information

Publication History

Publication Date:
09 July 2008 (online)

Also available at
    Permissions and Reprints

Millionen von Menschen leiden in Deutschland an der Zuckerkrankheit und ihren Folgen und ihre Zahl nimmt epidemieartig immer weiter zu. An ihren Komplikationen, wie z. B. Herzinfarkt und Schlaganfall, versterben ca. zwei Drittel der Patienten. Das Risiko der kardiovaskulären Sterblichkeit über sieben Jahre bei Patienten mit Diabetes, aber ohne klinische Hinweise auf einen Myokardinfarkt, ist genauso hoch ist wie bei nicht–diabetischen Postinfarkt–Patienten [5]. Auch ein „Prä–Diabetes”, d. h. IGT (impaired glucose tolerance) oder IFG (impaired fasting glucose tolerance), ist nicht nur ein Risikofaktor für die spätere Entwicklung eines Diabetes, sondern auch bereits für kardiovaskuläre Komplikationen und eine verfrühte Sterblichkeit. Die effektive Senkung des kardiovaskulären Risikos bei Patienten mit Diabetes ist eine multimodale Therapie, bei der die Senkung des LDL–Cholesterins und des Blutdruckes am effektivsten und am besten durch Studien belegt ist [2] [41].

In Germany, millions of persons suffer from diabetes and its sequels and their number goes on increasing like an epidemic. About two–thirds of the diabetic patients die from the complications of diabetes, such as myocardial infarction and stroke. The risk of cardiovascular mortality of diabetic patients without clinical indication of myocardial infarction over a period of seven years is exactly as high as with non–diabetic post–infarction patients. Even „pre–diabetic” patients, i.e. with IGT (impaired glucose tolerance) or IFG (impaired fasting glucose) are not only exposed to risk factors for the subsequent development of diabetes, but also to risks of cardiovascular complications and premature mortality. Effective lowering of cardiovascular risk in diabetic patients is a multimodal therapy. Studies have best confirmed the effectivity of this multimodal approach by a reduction of the LDL cholesterol and blood pressure.

Key words

pre–diabetic patients - impaired glucose tolerance - impaired fasting glucose - cardiovascular complications

Literatur

  • 1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).  JAMA. 2001;  285 2486-2497
    CrossrefGoogle Scholar
  • 2 American Diabetes Association . Standards of Medical Care in Diabetes.  Diabetes Care. 2008;  31
    Google Scholar
  • 3 Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. INTERHEART Study Investigators. . Effect of potentially modifiable risk factors assoviated with myocardial infarction in 52 contries (the INTERHEART study): case–control study.  Lancet. 2004;  364 937-952
    CrossrefPubMedGoogle Scholar
  • 4 Huxley R, Barzi F, Woodward M.. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta–analysis of 37 prospective cohort studies.  BMJ. 2006;  332 73-76
    CrossrefGoogle Scholar
  • 5 Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M.. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.  N Engl J Med. 1998;  339 229-243
    CrossrefGoogle Scholar
  • 6 Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M.. Type 2 Diabetes as a „Coronary Heart Disease Equivalent”.  Diabetes Care. 2005;  28 2901-2907
    CrossrefGoogle Scholar
  • 7 Schramm TK, Gislason GH, Kober L, Rasmussen S, Rasmussen JN, Abildstrom SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp–Pedersen C.. Diabetes patienets requiring glucose–lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk.  Circulation. 2008;  117 1945-1954
    CrossrefPubMedGoogle Scholar
  • 8 Rathmann W, Haastert B, Icks A, Löwel H, Meisinger C, Holle R, Giani G.. High prevalence of undiagnosed diabetes mellitus in Southern Germany: Target populations for efficient screening. The KORA Survey 2000.  Diabetologia. 2003;  46 182-189
    CrossrefPubMedGoogle Scholar
  • 9 Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J.. Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow–p.  Diabetes Care. 2003;  26 2910-2914
    Google Scholar
  • 10 Bartnik M, Ryden L, Ferrari R, Malmberg K, Pyorala K, Simoons M, Stands E, Soler–Soler J, Ohrvik J. Euro Heart Survey Investigators. . The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart.  Eur Heart J. 2004;  25 1990-1997
    CrossrefGoogle Scholar
  • 11 The DECODE study group . Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria.  Lancet. 1999;  354 610-611
    CrossrefGoogle Scholar
  • 12 Ridker PM, Buring JE, Cook NR, Rifai N.. C–reactive protein, the metabolic syndrome, and riks of incident cardiovascular events: an 8–year follow–up of 14.719 initially healthy American women.  Circulation. 2003;  107 391-397
    CrossrefPubMedGoogle Scholar
  • 13 Alexander GM, Landman PB, Teutsch SM, Haffner SM.. NCEP–defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants aged 50 years and older.  Diabetes. 2003;  52 1210
    CrossrefPubMedGoogle Scholar
  • 14 Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A.. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey.  Circulation. 2004;  209 42-46
    Google Scholar
  • 15 Peters AL, Davidson MB, Schriger DL, Hasselblad VA.. Clinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated haemoglobin levels.  JAMA. 1996;  276 1246-1252
    CrossrefGoogle Scholar
  • 16 The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. . Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes.  N Engl J Med. 2005;  353 2643-2653
    CrossrefGoogle Scholar
  • 17 Chiasson J–L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP–NIDDM Trial Research Group. . Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance.  JAMA. 2003;  290 486-494
    CrossrefGoogle Scholar
  • 18 UK Prospective Diabetes Study Group. . Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 43).  Lancet. 1998;  352 854-865
    CrossrefGoogle Scholar
  • 19 Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi–Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay RJ A. Heine, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags T V. Podar, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. PROactive investigators. . Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglit Azone Clinical Trial in Macro Vascular Events): a randomised controlled trial.  Lancet. 2005;  366 1279-1289
    CrossrefPubMedGoogle Scholar
  • 20 Charbonnel B, Dormandy J, Erdmann E, Massi–Benedetti M, Skene A. PROactive Study Group. . The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.  Diabetes Care. 2004;  27 1647-1653
    CrossrefGoogle Scholar
  • 21 Erdmann E, Dormandy JA, Charbonnel B, Massi–Benedetti M, Moules IK, Skene AM. PROactive Investigators. . The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) study.  J Am Coll Cardiol. 2007;  49 1772-1780
    CrossrefPubMedGoogle Scholar
  • 22 Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, Dormandy J. PROactive Investigators. . Effects of pioglitazone in patients with type 2 diabetes and previous stroke: results from the PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04).  Stroke. 2007;  38 865-873
    CrossrefPubMedGoogle Scholar
  • 23 Singh S, Loke YK, Furberg CD.. Long–term risk of cardiovascular events with rosiglitazone: a meta–analysis.  JAMA. 2007;  298 1189-1195
    CrossrefGoogle Scholar
  • 24 Solomon DH, Winkelmayr WC.. Cardiovascular risk and the thiazolidinediones: déjà vu all over again?.  JAMA. 2007;  298 1216-1218
    CrossrefGoogle Scholar
  • 25 www.nhlbi.nih.gov/health/prof/heart/other/ accord/
  • 26 The Action to Control Cardiovascular Risk in Diabetes Study Group. . Effects of intensive glucose lowering in type 2 diabetes.  N Engl J Med. 2008;  358 2545-2559
    CrossrefGoogle Scholar
  • 27 The ADVANCE Collaborative Group. . Intensive blood glucose control and vascular outcomes in patienets with type 2 diabetes.  N Engl J Med. 2008;  358 2560-2572
    CrossrefGoogle Scholar
  • 28 Raz I.. Hyperglycemia and its effect after myocardial infarction on cardiovascular outcomes in patienets with type 2 diabetes mellitus (HEART2D). American Diabetes Association, oral presentation, Monday, June 9: 2008
    Google Scholar
  • 29 Abraira C, Moritz TE, Duckworth WC.. Gylcemic control and cardiovascular outcomes – The VA Diabetes Trial. American Diabetes Association, oral presentations, Sunday, June. 8: 2008
    Google Scholar
  • 30 Anselmino M, Ohrvik J, Malmberg K, Standl E, Rydén L. Euro Heart Survey Investigators. . Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.  Eur Heart J. 2008;  29 177-184
    PubMedGoogle Scholar
  • 31 Suleiman M, Hammerman H, Boulos M, Kapeliovich MR, Suleiman A, Agman Y, Markiewicz W, Aronson D.. Fasting glucose is an important independent risk factor for 30–day mortality in patienets with acute myocardial infarction.  Circulation. 2005;  111 754-760
    CrossrefGoogle Scholar
  • 32 Kosiborod M, Inzucchi SE, Krimholz HM, Xiao L, Jones PG, Fiske S, Masoudi FA, Marso SP, Spertus JA.. Glucometrics in patients hospitalized with acute myocardial infacrtion: Defining the optimal outcome–based measure of risk.  Circulation. 2008;  117 1018-1027
    CrossrefGoogle Scholar
  • 33 Malmberg K, Norhammar A, Wedel H, Rydén L.. Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction.  Circulation. 1999;  99 2626-2632
    CrossrefGoogle Scholar
  • 34 Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp–Pedersen C, Waldström A. DIGAMI 2 Investigators. . Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity.  Eur Heart J. 2005;  26 650-661
    CrossrefPubMedGoogle Scholar
  • 35 Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L. CREATE–ECLA Trial Group Investigators. . Effect of glucose–insulin–potassium infusion on mortality in patients with acute ST–segment elevation myocardial infarction: the CREATE–ECLA randomized controlled trial.  JAMA. 2005;  293 489-491
    CrossrefGoogle Scholar
  • 36 Cheung NW, Wong VW, McLean M.. The hyperglycemia: Intensive insulin infusion in infarction (HI–5) study: a randomized controlled trial of insulin infusion therapy for myocardial infacrtion.  Diabetes Care. 2006;  29 765-770
    CrossrefGoogle Scholar
  • 37 Opie LH.. Metabolic management of acute myocardial infarction comes to the force and extends beyond control of hyperglycemia.  Circulation. 2008;  117 2172-2177
    CrossrefGoogle Scholar
  • 38 Deewania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P.. Hyperglycemia and acute coronary syndrome. A scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism.  Circulation. 2008;  117
    Google Scholar
  • 39 Goede P, Lund–Andersen H, Parving HH, Pedersen O.. Effect of a multifactorial intervention on mortality in type 2 diabetes.  N Engl J Med. 2008;  7 580-591
    Google Scholar
  • 40 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O.. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.  N Engl J Med. 2003;  30 383-393
    Google Scholar
  • 41 The task force on diabetes and cardiovascular diseases of the European society of cardiology (ESC) and of the European association for the study of diabetes (EASD). Guidelines on diabetes, pre–diabetes, and cardiovascular diseases: executive summary.  Eur Heart J. 2007;  28 88-136
    Google Scholar

Korrespondenz

Prof. Dr. med. Dirk Müller–Wieland

I. Medizinische Abteilung und Institut für Diabetes–Forschung, Asklepios Klinik St. Georg

Lohmühlenstr. 5

20099 Hamburg

Email: d.mueller-wieland@asklepios.com

      >